'On consolidated basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Zydus Lifesciences has increased 5.90% to Rs 6573.7 crore. Sales of pharmaceuticals segment has gone up 6.46% to Rs 5,716.20 crore (accounting for 86.96% of total sales). Sales of Consumer Products segment has gone up 2.30% to Rs 857.50 crore (accounting for 13.04% of total sales).
Profit before interest, tax and other unallocable items (PBIT) has jumped 1.10% to Rs 1,920.60 crore. PBIT of pharmaceuticals segment rose 1.58% to Rs 1,777.20 crore (accounting for 92.53% of total PBIT). PBIT of Consumer Products segment fell 4.46% to Rs 143.40 crore (accounting for 7.47% of total PBIT).
PBIT margin of pharmaceuticals segment fell from 32.59% to 31.09%. PBIT margin of Consumer Products segment fell from 17.91% to 16.72%. Overall PBI...
Pleaselogin & subscribe to view the full report.
More Reports
|
|